Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332262 | 0.93 | TRHR (0.66) | TRHR | |
| SCHEMBL5804619 | 0.92 | TRHR (0.54) | TRHR | |
| SCHEMBL11327973 | 0.89 | TRHR (0.66) | TRHR | |
| SCHEMBL7417306 | 0.87 | TRHR (0.64) | TRHR | |
| SCHEMBL14185753 | 0.87 | TRHR (0.68) | TRHR | |
| SCHEMBL3132248 | 0.87 | TRHR (0.68) | TRHR | |
| SCHEMBL11182741 | 0.85 | TRHR (0.66) | TRHR | |
| SCHEMBL11331704 | 0.85 | TRHR (0.66) | TRHR | |
| SCHEMBL1371608 | 0.85 | TRHR (0.66) | TRHR | |
| SCHEMBL27830909 | 0.85 | TRHR (0.66) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025069028-A1 | FERMENTATION-DERIVED FLAVOR MATERIALS PRODUCED FROM GRAINS AND GRAIN PRODUCTS AND EDIBLE COMPOSITIONS CONTAINING SAME | THE MEDITERRANEAN FOOD LAB LTD (IL) | 2025-04-03 | — | — | WO | disclosed |
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| CN-101945992-B | Protein-free gamete and embryo treatment and culture medium products | ALI BIN M ABDULLAH JAFFAR | 2014-03-26 | — | — | CN | disclosed |
| EP-2697361-A1 | PROTEIN-FREE CULTURE MEDIA PRODUCTS FOR MANUFACTURING VIRAL-BASED VACCINES | Cellcura Asa (NO) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697360-A1 | PROTEIN-FREE CULTURE MEDIA PRODUCTS | Ali Bin M. Abdullah, Jaffar (MY) | 2014-02-19 | — | — | EP | disclosed |
| US-20130196429-A1 | Protein-Free Gamete and Embryo Handling and culture Media Products | ALI BIN M ABUDALLAH JAFFAR (MY) | 2013-08-01 | — | — | US | disclosed |
| US-20130189670-A1 | Protein-Free Gamete and Embryo Handling and culture Media Products | ALI BIN M ABDULLAH JAFFAR (MY) | 2013-07-25 | — | — | US | disclosed |
| EP-2235160-B1 | PROTEIN-FREE GAMETE AND EMBRYO HANDLING AND CULTURE MEDIA PRODUCTS | ALI BIN M ABDULLAH JAFFAR (MY) | 2013-04-10 | — | — | EP | disclosed |
| US-8415094-B2 | Protein-free gamete and embryo handling and culture media products | ALI BIN M ABDULLAH JAFFAR (MY) | 2013-04-09 | — | — | US | disclosed |
| US-20040214781-A1 | Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same | MEYERHOFF JAMES L (US) | 2004-10-28 | — | — | US | disclosed |
| US-6716812-B1 | Modulation of sperm function | KING'S COLLEGE LONDON (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6475989-B1 | Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-11-05 | — | — | US | disclosed |
| US-6475989-B1 | Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-11-05 | — | — | US | disclosed |
| US-20020151502-A1 | Tri-peptides for neurological and neurobehavior applications | SATTIN ALBERT (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212076-A2 | STIMULATION OF SPERM FUNCTION | KING'S COLLEGE LONDON (GB) | 2002-06-12 | — | — | EP | disclosed |
| EP-1133313-A2 | CALCITONIN FOR THE MODULATION OF SPERM FUNCTION | KING'S COLLEGE LONDON (GB) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001028578-A2 | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | WRAIR (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001013932-A2 | STIMULATION OF SPERM FUNCTION | KING'S COLLEGE LONDON (GB) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000032224-A2 | CALCITONIN FOR THE MODULATION OF SPERM FUNCTION | KING'S COLLEGE LONDON (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | TRHR 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.